Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Konkret geht es um den Diabetes-Patienten mit kardiovaskulären Erkrankungen oder Risiken, die Herzinsuffizienz sowie die kardiovaskuläre Primär- und Sekundärprävention. Sind Sie hier schon auf dem neuesten Stand? Unsere Experten beleuchten, wo und warum das bisherige Procedere geändert werden soll und was in der Praxis sinnvoll ist. Holen Sie sich Ihr Update und 2 CME-Punkte beim MMW-Webinar am 24. April von 17.30 bis 19 Uhr. 
Erweiterte Suche
Anmelden
nach oben
Current Dermatology Reports
Erschienen in: Current Dermatology Reports 1/2017

06.03.2017 | Cutaneous Drug Reactions (J Brieva, Section Editor)

Topical JAK Inhibitors for the Treatment of Alopecia Areata and Vitiligo

Erschienen in: Current Dermatology Reports | Ausgabe 1/2017

Einloggen, um Zugang zu erhalten

Abstract

Purpose of Review

Alopecia areata (AA) and vitiligo are dermatological autoimmune diseases that, until recently, have had no specifically targeted therapies. Here, we review the future of therapies specifically targeted to the treatment of alopecia areata and vitiligo, both of which have JAK-STAT signaling implicated in their pathogenesis.

Recent Findings

With a greater understanding of disease mechanisms and pathogenesis, we are now able to target the immune dysfunction in autoimmune diseases with more precision than topical corticosteroids and calcineurin inhibitors. Inhibition of the JAK-STAT pathway has been shown to be effective in the treatment of AA, vitiligo, and in some patients with both diseases.

Summary

In this review, we summarize the current molecular and immunological understanding of AA and vitiligo, how JAK inhibition is increasingly positioned as a new therapy for autoimmune diseases, and the future of topical JAK inhibitors in the field of dermatology.
Literatur
1.
2.
• O'Shea JJ, et al. The JAK-STAT pathway: impact on human disease and therapeutic intervention. Annu Rev Med. 2015;66:311–28. Excellent perspective on the JAK-STAT pathway in relation to disease pathogenesis, and summary of strategies to target this pathway therapeutically CrossRefPubMed
3.
4.
Clark JD, Flanagan ME, Telliez JB. Discovery and development of Janus kinase (JAK) inhibitors for inflammatory diseases. J Med Chem. 2014;57(12):5023–38.CrossRefPubMed
5.
Menter MA, et al. Efficacy of tofacitinib for the treatment of moderate-to-severe chronic plaque psoriasis in patient subgroups from two randomised Phase 3 trials. J Drugs Dermatol. 2016;15(5):568–80.PubMed
6.
Sandborn WJ, et al. Tofacitinib, an oral Janus kinase inhibitor, in active ulcerative colitis. N Engl J Med. 2012;367(7):616–24.CrossRefPubMed
7.
Vincenti F, et al. Evaluation of the effect of tofacitinib exposure on outcomes in kidney transplant patients. Am J Transplant. 2015;15(6):1644–53.CrossRefPubMed
8.
Papp KA, et al. Efficacy and safety of tofacitinib, an oral Janus kinase inhibitor, in the treatment of psoriasis: a Phase 2b randomized placebo-controlled dose-ranging study. Br J Dermatol. 2012;167(3):668–77.CrossRefPubMed
9.
Bachelez H, et al. Tofacitinib versus etanercept or placebo in moderate-to-severe chronic plaque psoriasis: a phase 3 randomised non-inferiority trial. Lancet. 2015;386(9993):552–61.CrossRefPubMed
10.
Ports WC, et al. A randomized phase 2a efficacy and safety trial of the topical Janus kinase inhibitor tofacitinib in the treatment of chronic plaque psoriasis. Br J Dermatol. 2013;169(1):137–45.CrossRefPubMedPubMedCentral
11.
Punwani N, et al. Preliminary clinical activity of a topical JAK1/2 inhibitor in the treatment of psoriasis. J Am Acad Dermatol. 2012;67(4):658–64.CrossRefPubMed
12.
Fukuyama T, et al. Topically administered Janus-kinase inhibitors tofacitinib and oclacitinib display impressive antipruritic and anti-inflammatory responses in a model of allergic dermatitis. J Pharmacol Exp Ther. 2015;354(3):394–405.CrossRefPubMed
13.
Olivry T, et al. Treatment of canine atopic dermatitis: 2015 updated guidelines from the international committee on allergic diseases of animals (ICADA). BMC Vet Res. 2015;11:210.CrossRefPubMedPubMedCentral
14.
Tanimoto A, et al. Pharmacological properties of JTE-052: a novel potent JAK inhibitor that suppresses various inflammatory responses in vitro and in vivo. Inflamm Res. 2015;64(1):41–51.CrossRefPubMed
15.
Amano W, et al. The Janus kinase inhibitor JTE-052 improves skin barrier function through suppressing signal transducer and activator of transcription 3 signaling. J Allergy Clin Immunol. 2015;136(3):667–77. e7CrossRefPubMed
16.
Levy LL, Urban J, King BA. Treatment of recalcitrant atopic dermatitis with the oral Janus kinase inhibitor tofacitinib citrate. J Am Acad Dermatol. 2015;73(3):395–9.CrossRefPubMed
17.
•• Xing L, et al. Alopecia areata is driven by cytotoxic T lymphocytes and is reversed by JAK inhibition. Nat Med. 2014;20(9):1043–9. The first proof of a mechanism with information garnered from GWAS data, implicating the JAK-STAT pathway in the common effector pathways that drive CD8 NKG2D cells in AA CrossRefPubMedPubMedCentral
18.
•• Petukhova L, et al. Genome-wide association study in alopecia areata implicates both innate and adaptive immunity. Nature. 2010;466(7302):113–7. The pivotal GWAS that uncovered many possible genes associated with AA immunopathogenesis, including ULBP3 and CTLA-4 CrossRefPubMedPubMedCentral
19.
Betz RC, et al. Genome-wide meta-analysis in alopecia areata resolves HLA associations and reveals two new susceptibility loci. Nat Commun. 2015;6:5966.CrossRefPubMedPubMedCentral
20.
Dell'Anna ML, E. K, Hamzavi I, Harris J, Parsad D, Taieb A, Picardo M. Vitiligo. Nature Reviews Disease Primers. 2015;1(1):1–16.
21.
Kroll TM, et al. 4-Tertiary butyl phenol exposure sensitizes human melanocytes to dendritic cell-mediated killing: relevance to vitiligo. J Invest Dermatol. 2005;124(4):798–806.CrossRefPubMedPubMedCentral
22.
van den Boorn JG, et al. Skin-depigmenting agent monobenzone induces potent T-cell autoimmunity toward pigmented cells by tyrosinase haptenation and melanosome autophagy. J Invest Dermatol. 2011;131(6):1240–51.CrossRefPubMed
23.
Toosi S, Orlow SJ, Manga P. Vitiligo-inducing phenols activate the unfolded protein response in melanocytes resulting in upregulation of IL6 and IL8. J Invest Dermatol. 2012;132(11):2601–9.CrossRefPubMedPubMedCentral
24.
Harris JE. Cellular stress and innate inflammation in organ-specific autoimmunity: lessons learned from vitiligo. Immunol Rev. 2016;269(1):11–25.CrossRefPubMedPubMedCentral
25.
Harris JE. Vitiligo and alopecia areata: apples and oranges? Exp Dermatol. 2013;22(12):785–9.CrossRefPubMed
26.
Sadeghi S, et al. Study of Th1/Th2 balance in peripheral blood mononuclear cells of patients with alopecia areata. Acta Microbiol Immunol Hung. 2015;62(3):275–85.CrossRefPubMed
27.
Suarez-Farinas M, et al. Alopecia areata profiling shows TH1, TH2, and IL-23 cytokine activation without parallel TH17/TH22 skewing. J Allergy Clin Immunol. 2015;136(5):1277–87.CrossRefPubMed
28.
Gregg RK, et al. Mechanisms of spatial and temporal development of autoimmune vitiligo in tyrosinase-specific TCR transgenic mice. J Immunol. 2010;184(4):1909–17.CrossRefPubMedPubMedCentral
29.
Harris JE, et al. A mouse model of vitiligo with focused epidermal depigmentation requires IFN-gamma for autoreactive CD8(+) T-cell accumulation in the skin. J Invest Dermatol. 2012;132(7):1869–76.CrossRefPubMedPubMedCentral
30.
•• Rashighi M, et al. CXCL10 is critical for the progression and maintenance of depigmentation in a mouse model of vitiligo. Sci Transl Med. 2014;6(223):223ra23. Study in human patients and a mouse model that implicated the IFNg-CXCL10 cytokine axis in vitligo pathogenesis and provided the rationale for targeting the JAK-STAT pathway as a treatment strategy for vitiligo CrossRefPubMedPubMedCentral
31.
•• Harris JE, et al. Rapid skin repigmentation on oral ruxolitinib in a patient with coexistent vitiligo and alopecia areata (AA). J Am Acad Dermatol. 2016;74(2):370–1. The first striking case report that suggested a mechanistic link between AA and vitiligo, and proof of concept that JAK inhibitors will be effective for both diseases CrossRefPubMed
32.
Wang XX, et al. Increased expression of CXCR3 and its ligands in patients with vitiligo and CXCL10 as a potential clinical marker for vitiligo. Br J Dermatol. 2016;174(6):1318–26.CrossRefPubMed
33.
Rashighi M, Harris JE. Serum chemokines herald disease activity and treatment response in vitiligo patients. Br J Dermatol. 2016;174(6):1190–1.CrossRefPubMed
34.
Hordinsky M, Donati A. Alopecia areata: an evidence-based treatment update. Am J Clin Dermatol. 2014;15(3):231–46.CrossRefPubMed
35.
Oikarinen A, et al. The molecular basis of glucocorticoid-induced skin atrophy: topical glucocorticoid apparently decreases both collagen synthesis and the corresponding collagen mRNA level in human skin in vivo. Br J Dermatol. 1998;139(6):1106–10.CrossRefPubMed
36.
Ring J, Mohrenschlager M, Henkel V. The US FDA ‘black box’ warning for topical calcineurin inhibitors: an ongoing controversy. Drug Saf. 2008;31(3):185–98.CrossRefPubMed
37.
Sobell JM, Leonardi CL. Therapeutic development in psoriasis. Semin Cutan Med Surg. 2014;33(4 Suppl):S69–72.CrossRefPubMed
38.
Papp K, et al. Tildrakizumab (MK-3222), an anti-interleukin-23p19 monoclonal antibody, improves psoriasis in a phase IIb randomized placebo-controlled trial. Br J Dermatol. 2015;173(4):930–9.CrossRefPubMed
39.
Ritchlin CT, Krueger JG. New therapies for psoriasis and psoriatic arthritis. Curr Opin Rheumatol. 2016;28(3):204–10.CrossRefPubMed
40.
Redler S, et al. Investigation of selected cytokine genes suggests that IL2RA and the TNF/LTA locus are risk factors for severe alopecia areata. Br J Dermatol. 2012;167(6):1360–5.CrossRefPubMed
41.
Laddha NC, Dwivedi M, Begum R. Increased tumor necrosis factor (TNF)-alpha and its promoter polymorphisms correlate with disease progression and higher susceptibility towards vitiligo. PLoS One. 2012;7(12):e52298.CrossRefPubMedPubMedCentral
42.
Alghamdi KM, et al. Treatment of generalized vitiligo with anti-TNF-alpha agents. J Drugs Dermatol. 2012;11(4):534–9.PubMed
43.
Abramovits W, Losornio M. Failure of two TNF-alpha blockers to influence the course of alopecia areata. Skinmed. 2006;5(4):177–81.CrossRefPubMed
44.
Tauber M, et al. Alopecia areata occurring during anti-TNF therapy: a national multicenter prospective study. J Am Acad Dermatol. 2014;70(6):1146–9.CrossRefPubMed
45.
Maruthappu T, Leandro M, Morris SD. Deterioration of vitiligo and new onset of halo naevi observed in two patients receiving adalimumab. Dermatol Ther. 2013;26(4):370–2.CrossRefPubMed
46.
Mery-Bossard L, et al. New-onset vitiligo and progression of pre-existing vitiligo during treatment with biological agents in chronic inflammatory diseases. J Eur Acad Dermatol Venereol. 2016.
47.
48.
Jabbari A, et al. Treatment of an alopecia areata patient with tofacitinib results in regrowth of hair and changes in serum and skin biomarkers. Exp Dermatol. 2016.
49.
• Craiglow BG, King BA. Tofacitinib citrate for the treatment of vitiligo: a pathogenesis-directed therapy. JAMA Dermatol. 2015;151(10):1110–2. First reported attempt to treat vitiligo with tofacitinib CrossRefPubMed
50.
51.
Pieri L, Guglielmelli P, Vannucchi AM. Ruxolitinib-induced reversal of alopecia universalis in a patient with essential thrombocythemia. Am J Hematol. 2015;90(1):82–3.CrossRefPubMed
52.
Higgins E, et al. Use of ruxolitinib to successfully treat chronic mucocutaneous candidiasis caused by gain-of-function signal transducer and activator of transcription 1 (STAT1) mutation. J Allergy Clin Immunol. 2015;135(2):551–3.CrossRefPubMed
53.
Gupta AK, Carviel JL, Abramovits W. Efficacy of tofacitinib in treatment of alopecia universalis in two patients. J Eur Acad Dermatol Venereol. 2016;30(8):1373–8.CrossRefPubMed
54.
55.
56.
Wang Y, et al. Effective treatment of experimental ragweed-induced asthma with STAT-6-IP, a topically delivered cell-penetrating peptide. Clin Exp Allergy. 2011;41(11):1622–30.CrossRefPubMed
57.
Fridman JS, et al. Preclinical evaluation of local JAK1 and JAK2 inhibition in cutaneous inflammation. J Invest Dermatol. 2011;131(9):1838–44.CrossRefPubMed
58.
Craiglow BG, Tavares D, King BA. Topical ruxolitinib for the treatment of alopecia universalis. JAMA Dermatol. 2016;152(4):490–1.CrossRefPubMed
59.
Bissonnette R, et al. Topical tofacitinib for atopic dermatitis: a phase 2a randomised trial. Br J Dermatol. 2016.
60.
61.
Punwani N, et al. Downmodulation of key inflammatory cell markers with a topical Janus kinase 1/2 inhibitor. Br J Dermatol. 2015;173(4):989–97.CrossRefPubMed
62.
• Richmond JM, et al. Keratinocyte-derived chemokines orchestrate T cell positioning in the epidermis during vitiligo and may serve as biomarkers of disease. J Invest Dermatol. 2016. Study that elegantly places the epidermal cells in the center of vitiligo pathogenesis, thus allowing it to be a suitable target for topical therapy.
Metadaten
Titel
Topical JAK Inhibitors for the Treatment of Alopecia Areata and Vitiligo
Publikationsdatum
06.03.2017
Erschienen in
Current Dermatology Reports / Ausgabe 1/2017
Elektronische ISSN: 2162-4933
DOI
https://doi.org/10.1007/s13671-017-0163-z

Weitere Artikel der Ausgabe 1/2017

Current Dermatology Reports 1/2017 Zur Ausgabe

Psoriasis (J Wu, Section Editor)

Update on Ustekinumab for Psoriasis

Atopic Dermatitis (T Bieber, Section Editor)

Comorbidities of Atopic Dermatitis: Beyond Rhinitis and Asthma

Hospital-based Dermatology (D Kroshinsky, Section Editor)

Hair and Nail Manifestations of Systemic Disease

Hospital- based Dermatology (D Kroshinsky, Section Editor)

Contact Dermatitis in the Hospitalized Patient

Leitlinien kompakt für die Dermatologie

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Kostenlos registrieren

Neu im Fachgebiet Dermatologie

16.04.2024 | Infektiologie | Nachrichten

Kein Abstrich bei chronischen Wunden ohne Entzündungszeichen!

12.04.2024 | Vitiligo | Nachrichten

Vitiligo: Prävalenz steigt und viele Erkrankte werden spät behandelt

12.04.2024 | Atopische Dermatitis | Nachrichten

Dupilumab ist mit kutanen T-Zell-Lymphomen assoziiert

09.04.2024 | DGP 2024 | Kongressbericht | Nachrichten

Chemotherapie mit Hindernissen
weitere anzeigen

Update Dermatologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise